孕期接种百白破疫苗与幼儿健康结局
该研究基于加拿大安大略省2012年4月至2017年3月所有活产儿的回顾性队列,将孕期暴露于Tdap疫苗的儿童按1:5倾向评分匹配未暴露儿童,随访至6岁。结果显示孕期Tdap暴露未增加儿童不良健康结局风险,且上呼吸道感染、胃肠道感染及急诊/住院服务使用呈反向关联。结论支持孕期接种Tdap的长期安全性。
要点
- 孕期Tdap暴露未增加儿童免疫相关及非免疫相关不良结局风险。
- 孕期Tdap暴露与上呼吸道感染、胃肠道感染及急诊/住院使用呈反向关联。
- 研究支持孕期接种Tdap疫苗的长期安全性。
核心结论
- 孕期接种Tdap疫苗与儿童早期不良健康结局风险增加无关,支持其长期安全性。
研究设计与样本
- 基于加拿大安大略省多个全省健康行政数据库的回顾性队列研究,纳入2012年4月至2017年3月所有活产儿,随访至6岁。
- 孕期暴露于Tdap的儿童按1:5倾向评分匹配未暴露儿童,疫苗暴露通过疫苗专用收费代码确定。
主要发现
- 孕期Tdap暴露未显著增加儿童不良结局风险;上呼吸道感染调整发病率比0.94(95%CI 0.90-0.99),胃肠道感染0.85(95%CI 0.79-0.91),急诊和住院服务使用0.93(95%CI 0.91-0.96)。
临床怎么用
- 儿科医生可向孕妇传递孕期接种Tdap疫苗不增加儿童早期不良健康结局风险的证据。
- 对于孕期已接种Tdap的母亲所生儿童,无需因疫苗暴露而进行额外健康监测。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Maternal immunization with tetanus, diphtheria, and acellular pertussis vaccine (Tdap) is routinely recommended in many countries as a strategy to protect young infants against severe pertussis infection; few studies have assessed whether prenatal exposure to the vaccine is associated with any longer-term adverse health effects in children. We evaluated the long-term safety of exposure to Tdap vaccination during pregnancy. METHODS: Population-based retrospective cohort study conducted in Ontario, Canada using multiple linked province-wide health administrative databases. All live births between April 2012 and March 2017 were included, and children were followed for up to 6 years to ascertain study outcomes. Children exposed to prenatal Tdap were propensity score matched to unexposed children at a 1:5 ratio. Tdap vaccination during pregnancy was ascertained by using vaccine-specific fee codes. Immune-related (infectious diseases, asthma) and nonimmune-related (neoplasm, sensory disorders) outcomes and a nonspecific morbidity outcome (urgent or inpatient health service use) were evaluated from birth to end of follow-up. RESULTS: Of 625 643 live births, 12 045 (1.9%) were exposed to Tdap in utero. There were no significant increased risks of adverse childhood outcomes and prenatal Tdap exposure; however, we observed inverse associations (adjusted incidence rate ratio [95% confidence interval]) with upper respiratory infections (0.94 [0.90-0.99]), gastrointestinal infections (0.85 [0.79-0.91]), and urgent and inpatient health service use (0.93 [0.91-0.96]). CONCLUSIONS: Exposure to Tdap vaccination in pregnancy was not associated with any increased risk of adverse health outcomes in early childhood, supporting the long-term safety of Tdap administration in pregnancy.
引用
- Laverty M, Crowcroft N, Bolotin S, et al. Health Outcomes in Young Children Following Pertussis Vaccination During Pregnancy. Pediatrics. 2021. PMID: 33875535. doi:10.1542/peds.2020-042507
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。